Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery
Alpha Wealth Funds, LLC, in its Q1 2026 investor letter, highlighted DexCom, Inc. (NASDAQ:DXCM) despite losing 7.14% in the quarter due to the War in Iran. Although the fund sees potential in DXCM as a medical technology leader, it believes AI stocks currently offer greater promise for higher and quicker returns. DexCom reported Q1 2026 revenue of $1.19 billion, and its shares have seen significant volatility but also a 16.78% one-month return.
Handelsbanken Fonder AB Increases Position in Labcorp Holdings Inc. $LH
Handelsbanken Fonder AB has increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 17.4% in the fourth quarter, bringing its total holding to 32,199 shares valued at $8.08 million. This increase follows Labcorp's strong Q4 earnings, which beat expectations with $4.25 EPS on $3.54 billion revenue, and raised its FY2026 guidance. Analyst sentiment remains positive with a "Moderate Buy" consensus and a target price of $308.00, alongside a declared quarterly dividend of $0.72 per share.
DexCom Might Finally Be Cheap Enough (NASDAQ:DXCM)
DexCom (DXCM) stock is now rated a 'Buy' due to improved fundamentals, a 15% lower stock price, and strong Q1/26 results showing 15% revenue growth and 90.9% operating income growth. Key drivers for future growth include international expansion, increased U.S. coverage for type 2 diabetics, and a $1 billion share buyback in 2026. The company appears slightly undervalued, with a P/FCF of 20 and intrinsic value estimates up to $115, suggesting high double-digit growth prospects.
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
Beta Bionics announced an updated commercialization timeline for its Mint™ patch pump, expecting full commercialization by the end of Q2 2027, pending FDA regulatory clearance. The timeline is based on initial FDA responses and progress in manufacturing scaling. Mint is designed to be compatible with Beta Bionics’ adaptive insulin dosing algorithm, offering innovative features for people with diabetes.
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX)
Beta Bionics (NASDAQ: BBNX) has announced that it targets the full commercialization of Mint, its patch insulin pump, by the end of Q2 2027, subject to FDA regulatory clearance. The updated timeline is based on initial FDA responses and progress in scaling manufacturing, anticipating capacity to meet launch demand. Mint is designed to offer a 200-unit insulin reservoir, three days of wear, smartphone control, and compatibility with leading continuous glucose monitors and Beta Bionics’ adaptive dosing algorithm.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. stock exhibited a strong performance on a recent trading day, closing higher and outperforming its competitors. The stock also surpassed the S&P 500 in daily gains.
IFP Advisors Inc Boosts Stake in Medtronic PLC $MDT
IFP Advisors Inc increased its stake in Medtronic PLC by 33.4% in the fourth quarter, now owning 57,287 shares valued at $5,503,000. Other institutional investors also adjusted their positions in Medtronic, which has a current market cap of $100.26 billion and recently announced a quarterly dividend. The medical technology company's stock is trading down 0.6% and has received a "Moderate Buy" consensus rating from analysts.
Dexcom stock (US2521311074): Insider sale adds focus on shares
Dexcom (US2521311074) is gaining attention after a recent SEC filing revealed its EVP and Chief Legal Officer, Michael Jon Brown, sold 1,700 shares under a pre-arranged Rule 10b5-1 plan. This transaction, executed at $59.91 per share, highlights the diabetes technology company for US investors who closely monitor CGM demand and insider activities. Despite the sale, Brown retains a significant stake, and the company's performance remains tied to CGM adoption and competitive landscape.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) shares rose 6.71% to $71.44 on a strong trading day where the S&P 500 and Dow Jones Industrial Average also saw significant gains. This marks the fourth consecutive day of increases for DexCom's stock. The company's performance outpaced its competitors amidst a favorable market session.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
Labcorp has launched MyLabcorp™, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The app integrates lab results, AI-enabled insights, and educational content, leveraging OpenAI models for personalized explanations and conversational interactions. It aims to empower users with better health context and support more informed discussions with healthcare providers, all within a secure, HIPAA-compliant environment.
HighTower Advisors LLC Has $138.80 Million Stock Holdings in Medtronic PLC $MDT
HighTower Advisors LLC reduced its stake in Medtronic PLC by 1.1% in the fourth quarter, now holding 1,444,921 shares valued at $138.80 million. Despite this, other major institutional investors like Vanguard Group Inc., State Street Corp, and Bank of New York Mellon Corp significantly increased their holdings in the medical technology company. Wall Street analysts currently rate Medtronic as a "Moderate Buy" with an average target price of $107.80.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $8.37 Million in Medtronic PLC $MDT
Fideuram Intesa Sanpaolo Private Banking S.P.A. has acquired a new stake of 87,140 shares in Medtronic PLC, valued at approximately $8.37 million. This investment highlights continued institutional interest in Medtronic, with 82.06% of the stock held by institutions and hedge funds. The medical technology company recently reported strong quarterly earnings, exceeding analyst expectations with $1.36 EPS on $9.02 billion in revenue, and maintains a "Moderate Buy" consensus rating among analysts.
Dexcom stock (US2521311074): Insider sale and sharp price jump put CGM specialist in focus
Dexcom (DXCM) experienced a significant share price jump in mid-May, closing at $65.09, while its chief legal officer, Michael Jon Brown, sold 1,700 shares as part of a pre-arranged 10b5-1 trading plan. The company, a specialist in continuous glucose monitoring (CGM), generates revenue primarily through recurring sensor sales in the US and international markets. Investors closely monitor Dexcom's product innovation, regulatory approvals, and reimbursement decisions, as these factors, along with competitive dynamics, influence its stock performance and growth trajectory.
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
DexCom (DXCM) is set to launch its new Dexcom Flex continuous glucose monitoring (CGM) system in Germany, targeting adults with Type 2 diabetes who are not on intensive insulin therapy. This move aims to broaden access to CGM technology, aligning with the company's strategy to enhance personalized care for a wider patient population. The launch is expected to strengthen DexCom's market position, support long-term revenue growth, and capitalize on the expanding diabetes technology market.
Resmed, Oura partner on sleep health education, care
Resmed and Oura have announced a partnership to expand access to sleep health education and care, aiming to help individuals better understand and improve their sleep. The collaboration will allow Oura Ring users with signs of nighttime breathing disturbances to access Resmed's resources, including educational materials, sleep assessments, and connections to healthcare providers. This initiative seeks to bridge the awareness gap regarding sleep disorders like obstructive sleep apnea (OSA) and encourage users to seek clinical evaluation.
Henry Schein stock (US42548G1040): dental distributor in focus after latest quarterly update
Henry Schein, a major dental and medical distributor, recently released new quarterly figures and an updated outlook, drawing investor attention. The article examines the company's business model, key revenue drivers in its dental and medical segments, and the impact of factors like inflation and procedure volumes on its performance. It concludes that while Henry Schein maintains a strong position through recurring sales and technology offerings, it faces ongoing challenges from economic cycles and competitive pricing.
Dexcom Inc. stock (US2521311074): buyback, 2030 targets and activist deal fire up DXCM
Dexcom Inc. shares have seen a significant jump after the company announced a $1 billion share buyback program, set ambitious financial targets for 2030, and reached a cooperation agreement with activist investor Elliott Investment Management. The market reacted positively, pushing the stock higher, with analysts providing generally supportive commentary, albeit with varying price targets. This strategic update focuses on scaling Dexcom's continuous glucose monitoring (CGM) platform, expanding into new segments, and improving profitability, which is relevant for US investors focused on medical technology and long-term healthcare trends.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) stock saw a strong trading day, rising 1.34% to $127.00, outperforming both its industry competitors and the broader market indices like the S&P 500 and Dow Jones Industrial Average. Despite the positive daily performance, the stock remains below its 52-week high, having fallen 2.87% over the last five days.
Qualys (QLYS) Rallies As Earnings Beat And FedRAMP Win Draw Traders
Qualys (QLYS) stocks rallied by 8.84% due to strong Q1 earnings, with non-GAAP EPS beating estimates and revenue exceeding expectations, driven by AI-driven pre-breach risk management. The company also secured a FedRAMP High Authorization for its TotalCloud CNAPP, opening doors to federal and regulated customers. While several banks adjusted price targets, the underlying fundamentals of high margins, strong cash flow, and low leverage suggest a “good company” status, making it an interesting stock for active traders focused on key levels and trend analysis.
Embecta closes Owen Mumford acquisition for up to $201M
Embecta has finalized its acquisition of Owen Mumford Holdings for an upfront payment of 100 million pounds plus up to 50 million pounds in performance-based payments, totaling potentially $201 million. This acquisition helps Embecta, traditionally focused on diabetes care, expand into broader medical supplies and markets such as autoimmune diseases and anaphylaxis, leveraging Owen Mumford's auto-injector platform and manufacturing capabilities. The deal is expected to contribute to Embecta's revenue growth starting in its 2027 fiscal year.
LKQ Corporation Notice of June 22, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice regarding a class action securities lawsuit against LKQ Corporation (NASDAQ: LKQ). The lawsuit alleges securities fraud between February 27, 2023, and July 23, 2025, related to misrepresentations concerning the acquisition and integration of FinishMaster. Investors who suffered losses have until June 22, 2026, to request to be appointed as lead plaintiff.
Senseonics Holdings Inc (FRA:6L60) Stock Price, Trades & News
This page provides a comprehensive overview of Senseonics Holdings Inc (FRA:6L60), a medical technology company specializing in continuous glucose monitoring systems. It details the company's current stock price, financial strength, growth, momentum, liquidity, and profitability ranks, along with a business description and upcoming events. The report also highlights three severe warning signs detected by GuruFocus for the stock.
New Philips heart imaging cuts X-ray dose by over half in complex procedures
Philips will present new imaging, physiology, and AI-enabled guidance solutions at EuroPCR 2026, aimed at reducing X-ray radiation doses by over 50% in complex coronary and structural heart procedures. Key innovations include SmartIQ technology, IntraSight Plus, and DeviceGuide, designed to improve workflow efficiency and patient care while minimizing radiation exposure for both patients and staff. The company emphasizes integrated solutions to manage procedural complexity without compromising image quality or clinical confidence.
DexCom (DXCM) Introduces Dexcom Flex for Type 2 Diabetes Patients
DexCom (DXCM) has launched its new continuous glucose monitoring (CGM) system, Dexcom Flex, designed for adults with Type 2 diabetes who do not use intensive insulin therapy, with its initial rollout in Germany. Despite recent insider selling and declining gross margins, the company holds a strong GF Score™ of 88/100 and its P/E ratio is near a 10-year low, suggesting potential undervaluation. This strategic product expansion aims to broaden the accessibility of CGM technology and improve patient quality of life.
DexCom, Inc. Stock 12‑Month Price Target Cut to $82.28, Implies 34% Upside
The average 12-month price target for DexCom, Inc. (DXCM) stock has been lowered slightly from $83.08 to $82.28 by 25 analysts. This revised target still suggests a 34% potential upside based on the May 15 closing price. The consensus analyst rating for DXCM remains a "Buy," with 27 out of 32 analysts recommending a Buy.
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo
The wearables in the pharma & biotech market are projected to grow significantly from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, driven by advancements in biosensor technology, miniaturization, and digitization, alongside increasing global internet connectivity. Continuous Glucose Monitors (CGMs) currently lead the product segment due to strong clinical backing and expanding patient eligibility. Pharmaceutical and biotech companies are the largest end-users, with Asia Pacific showing the highest growth potential due to its improving digital health infrastructure and increasing clinical research.
BofA Securities Adjusts Price Target on DexCom to $80 From $100
BofA Securities has lowered its price target for DexCom (NASDAQ:DXCM) shares from $100 to $80. The article mentions this change and provides market data for DexCom, including its real-time stock price and recent news headlines related to the company's performance and analyst ratings.
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
Dexcom has announced the launch of Dexcom Flex in Germany, a new continuous glucose monitoring (CGM) system tailored for adults with Type 2 diabetes who do not use intensive insulin therapy. This system aims to expand access to CGM technology for people using basal insulin, oral medications, or GLP-1 receptor agonists, offering personalized glucose insights and optional low glucose alerts. The introduction of Dexcom Flex reflects a shift towards personalized diabetes care, with studies suggesting that CGM use can improve health outcomes and reduce diabetes-related complications for Type 2 diabetes patients.
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
DexCom, Inc. announced Dexcom Flex, a new continuous glucose monitoring (CGM) system specifically designed for adults with Type 2 diabetes who do not use intensive insulin therapy. The system, launching soon in Germany, aims to expand CGM access, offering real-time glucose monitoring, personalized insights, and optional low glucose alerts to support tailored diabetes management and potentially reduce diabetes-related complications. This initiative reflects Dexcom's commitment to personalized diabetes care and addressing the growing global challenge of Type 2 diabetes.
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
Dexcom has announced Dexcom Flex, a new continuous glucose monitoring (CGM) system designed for adults with Type 2 diabetes who do not use intensive insulin therapy. Set to launch in Germany, the system provides real-time glucose data, personalized insights, and simplified tracking to help users and healthcare providers manage glucose patterns effectively. This move expands CGM access for a broader Type 2 diabetes population, aiming to improve health outcomes and reduce diabetes-related complications.
DexCom Stock Jumps After Diabetes Management Firm Reaches Agreement With Elliott Investment Management
DexCom's stock surged almost 7% after activist investor Elliott Investment Management took a major stake and reached a cooperation agreement with the company's board, including the addition of two new independent directors. The announcement coincided with DexCom's 2026 Investor Day, where the company outlined plans for expanding beyond diabetes devices, announced a new $1 billion share buyback program, and set ambitious long-range financial targets through 2030, all of which garnered strong support from Wall Street analysts. The stock's performance was particularly notable given the broader market's decline on the same day.
DexCom Stock Jumps As 2030 Targets Ignite Bullish Trading
DexCom's stock surged over 5% following the announcement of ambitious 2030 financial targets, including double-digit annual revenue growth, high gross margins, and a $1 billion share buyback. Analysts from RBC and Benchmark reiterated "Outperform" and "Buy" ratings, respectively, citing conservative guidance and market expansion. The company is also enhancing governance with Elliott Management, further strengthening investor confidence despite some lingering headline risks.
iA Global Asset Management Inc. Invests $5.81 Million in Medtronic PLC $MDT
iA Global Asset Management Inc. recently acquired a new position in Medtronic PLC, purchasing 60,494 shares valued at approximately $5.81 million during the fourth quarter. Medtronic continues to see strong institutional interest, with 82.06% of the stock held by such investors, and analysts have given the stock a "Moderate Buy" rating with a consensus target price of $107.80. The company reported solid quarterly earnings, beating EPS and revenue estimates, and reaffirmed its FY2026 guidance.
Could Solana (SOL) ETFs Outperform Ripple (XRP) ETFs In 2026?
The article discusses whether Solana (SOL) ETFs will outperform Ripple (XRP) ETFs in 2026, driven by institutional capital flows rather than traditional crypto narratives. Solana ETFs show higher growth sensitivity to inflows, whereas XRP ETFs reflect a more stable institutional allocation profile due to its payments utility and regulatory clarity. The performance gap will depend on whether market capital favors high-risk growth exposure (Solana) or steady institutional allocation (XRP).
Elliott strikes Dexcom board settlement after taking stake
Elliott Management has reached a settlement with Dexcom, a medical device company, regarding board representation. This agreement comes after the activist investor took a stake in Dexcom, suggesting a move to influence the company's strategic direction. The terms of the settlement were not detailed in the provided content.
CNRG and PBW Both Track Clean Energy but One Fell 61% in the Last Downturn While the Other Lost 23%
This article compares two clean energy ETFs, SPDR S&P Kensho Clean Power ETF (CNRG) and Invesco WilderHill Clean Energy ETF (PBW), highlighting their differing mandates and performance during market fluctuations. CNRG focuses on clean electricity generation and utilities, providing more downside protection, while PBW invests across the broader clean energy value chain, including EV and battery companies, leading to higher returns in risk-on environments but also larger drawdowns. The comparison helps investors decide which ETF aligns with their risk tolerance and investment strategy.
Medtronic PLC $MDT Shares Sold by Saratoga Research & Investment Management
Saratoga Research & Investment Management slightly reduced its stake in Medtronic PLC by 1.3% in the fourth quarter, though the medical technology company remains a significant holding, representing about 5.8% of the fund’s portfolio. Despite some analyst target cuts and a downgrade from Weiss Ratings, Medtronic holds a "Moderate Buy" consensus rating with an average price target of $107.80. The company recently reported strong quarterly results, beating EPS and revenue estimates, and offers a quarterly dividend of $0.71, yielding 3.7%.
Stephens Investment Management Group LLC Boosts Stock Position in DexCom, Inc. $DXCM
Stephens Investment Management Group LLC significantly increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 21.1% in the fourth quarter, accumulating over one million shares valued at $69.2 million. This move is part of a broader trend of strong institutional interest, with hedge funds and other institutions now owning 97.75% of DexCom's stock. The company recently exceeded earnings and revenue expectations and has a positive outlook, backed by a $1 billion share buyback program and a 2030 growth plan targeting at least 10% annual revenue growth.
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors
Natera Inc. experienced a stock price drop of over 5% following insider selling by co-founder Jonathan Sheena and a broader market pullback in high-growth diagnostics. Despite strong revenue growth in its molecular diagnostics business, particularly in oncology and organ health testing, the company continues to report net losses due to ongoing investments. The insider selling, though a relatively small portion of Sheena's holdings and conducted via a pre-arranged plan, contributed to short-term cautious sentiment among investors, compounded by negative technical signals.
If You Want Commodity Exposure Without Futures Contracts, Start Here
The VanEck Natural Resources ETF (HAP) offers commodity exposure through equities instead of futures contracts, addressing issues like roll yield and K-1 tax forms. HAP invests in companies involved in six commodity sub-themes, providing inflation resilience and participation in long-term demand for resources. While it offers operating leverage and cash flow, investors should be aware of equity beta in sell-offs and cycle sensitivity.
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment
Abbott Laboratories (ABT) is under scrutiny due to sales declines in its Nutrition business, legal uncertainties, and cautious analyst sentiment, despite product launches and recovering volumes. While the stock has seen a significant pullback over the last year, Simply Wall St's narrative suggests it is 25.8% undervalued with a fair value of $113.88, viewing it as a long-duration growth story. However, this valuation depends on the easing of Nutrition headwinds and the successful integration of Exact Sciences without further pressure from legal issues.
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom outlined its long-term growth plan during its 2026 Investor Day, targeting over 10% annual revenue growth through 2030, along with margin expansion and increased free cash flow. Key initiatives include the rollout of the G7 15 Day product, the anticipated launch of the G8 continuous glucose monitor around late 2027 or early 2028, and significant expansion of insurance coverage, particularly for Type 2 diabetes patients not using insulin. The company also announced a $1 billion share repurchase program for 2026 and committed to returning at least 50% of annual free cash flow to buybacks going forward.
SPHQ Outpaced JQUA by 500 Basis Points Over Five Years Despite Being the Riskier Trade
The article compares two quality-factor ETFs, SPHQ and JQUA, noting that Invesco S&P 500 Quality ETF (SPHQ) has surprisingly outperformed JPMorgan U.S. Quality Factor ETF (JQUA) over a five-year period, despite being the more concentrated and theoretically riskier option. While JQUA showed better resilience during the 2022 market downturn, SPHQ demonstrated stronger recovery and overall returns across various timeframes. The author concludes that SPHQ is a better choice for investors willing to accept deeper drawdowns for higher returns, while JQUA suits those seeking a broader, smoother ride through rate shocks.
AustralianSuper Pty Ltd Increases Stock Position in Medtronic PLC $MDT
AustralianSuper Pty Ltd significantly increased its stake in Medtronic PLC (NYSE:MDT) by 32.4% in the fourth quarter, purchasing an additional 53,006 shares to bring its total holdings to 216,362 shares valued at approximately $20.8 million. Medtronic continues to see strong institutional interest, with hedge funds and other large institutions owning 82.06% of the company's stock. The company recently surpassed analyst earnings expectations with $9.02 billion in revenue and maintains a quarterly dividend of $0.71 per share, yielding about 3.7% annually.
Insulet Corporation Trade Ideas — BOATS:PODD
This article compiles several trading ideas and analyses for Insulet Corporation (PODD) from various contributors on TradingView. It covers fundamental and technical analysis, including earnings growth, sales figures, resistance and support levels, and chart patterns like cup and handle formations. The contributors offer diverse perspectives on potential entry points, profit targets, and stop-loss levels, indicating both bullish and cautious sentiments for the stock.
Allworth Financial LP Has $8.32 Million Stock Position in Medtronic PLC $MDT
Allworth Financial LP increased its stake in Medtronic PLC (NYSE:MDT) by 59.4% in the fourth quarter, bringing its total holdings to 86,611 shares valued at $8.32 million. Other institutional investors like Vanguard Group Inc. and State Street Corp also significantly increased their positions in the medical technology company. Medtronic recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.71 per share.
DexCom, Inc. $DXCM Shares Sold by Swiss Life Asset Management Ltd
Swiss Life Asset Management Ltd significantly reduced its stake in DexCom (DXCM) by 28.3% in the fourth quarter of the previous year, selling 24,303 shares and retaining 61,667 shares valued at approximately $4.09 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $83.22. The company recently exceeded earnings and revenue expectations, and its stock is trading near its 52-week low.
DexCom (DXCM) Posts Upbeat 2026, Climbs 6.6%
DexCom (DXCM) shares rose 6.59% after the company provided an upbeat growth outlook for the full-year period at its investor day. DexCom set a target of 10% annual organic revenue growth through 2030 and increased its non-GAAP gross, operating, and adjusted EBITDA margins. The company also announced plans to add two independent directors with medical technology and operations experience, following collaboration with activist investor Elliott Investment Management LP.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) stock saw a strong trading day, outperforming competitors and the broader market. Despite closing lower, the company's shares surpassed the S&P 500 and Dow. Competitors like Abbott Laboratories and Medtronic PLC underperformed DexCom on the same day.
Michael Brown reports two 1,700-share DXCM sales through Morgan Stanley (DXCM)
Michael Brown reported two separate sales of 1,700 shares of Dexcom (DXCM) Common Stock through Morgan Stanley, occurring on March 16, 2026, and April 15, 2026. The sales amounted to $110,245.00 and $107,168.00, respectively. The filing also referenced 1,700 restricted shares with a trade date of March 8, 2026.
